India, May 14 -- Senti Biosciences Holdings Inc. (SNTI), a clinical-stage biotechnology company, on Thursday announced its first quarter financial results, and highlighted various business developments.
The company is developing SENTI-202 for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Q1 2026:
Net losses amounted to $4.22 million, or $0.14 per share, while in the same period in the prior year, the net loss was $14.11 million, or $1.41 per share.
Research and development (R&D) expenses were $5.3 million, relatively higher than the $3.9 million reported in the previous year.
Cash, cash equivalents, and marketable securities on March 31, 2026, amounted to $8.93 million.
googletag.cmd.push(function()...